KRAS and cancer: KRAS missense mutations, which occur at high rates in pancreatic (more than 85% of cases), colorectal (~40%) and non-small cell lung (~30%) cancers, lead to persistent activation of the protein’s GTPase activity and downstream signaling through the PI3K-AKT-mTOR, MAP kinase and RAL pathways, among others [7].